SHEL.UK

2,976

+0.42%↑

BP

470.6

-0.81%↓

SHEL.UK

2,976

+0.42%↑

BP

470.6

-0.81%↓

SHEL.UK

2,976

+0.42%↑

BP

470.6

-0.81%↓

SHEL.UK

2,976

+0.42%↑

BP

470.6

-0.81%↓

SHEL.UK

2,976

+0.42%↑

BP

470.6

-0.81%↓

Search

Smith & Nephew PLC

Open

1,328 -0.6

Overview

Share price change

24h

Current

Min

1323

Max

1350.5

Key metrics

By Trading Economics

Income

296M

Sales

3B

P/E

Sector Avg

32.354

48.535

EPS

0.429

Dividend yield

2.89

Profit margin

9.895

Employees

17,000

EBITDA

723M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+11.53% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.89%

3.96%

Next Earnings

2 mar 2026

Market Stats

By TradingEconomics

Market Cap

11B

Previous open

1328.6

Previous close

1328

Smith & Nephew PLC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

23 lut 2026, 22:53 UTC

Acquisitions, Mergers, Takeovers

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23 lut 2026, 22:36 UTC

Earnings

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23 lut 2026, 22:32 UTC

Earnings

Woodside Energy Fiscal Year Net Profit Falls 24%

23 lut 2026, 23:58 UTC

Market Talk
Earnings

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23 lut 2026, 23:58 UTC

Market Talk
Earnings

Global Energy Roundup: Market Talk

23 lut 2026, 23:47 UTC

Market Talk

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23 lut 2026, 23:43 UTC

Market Talk

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23 lut 2026, 23:41 UTC

Acquisitions, Mergers, Takeovers

Crescent Capital Partners Owns 53% of ClearView Wealth

23 lut 2026, 23:40 UTC

Acquisitions, Mergers, Takeovers

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23 lut 2026, 23:40 UTC

Acquisitions, Mergers, Takeovers

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23 lut 2026, 23:40 UTC

Market Talk

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23 lut 2026, 23:40 UTC

Acquisitions, Mergers, Takeovers

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23 lut 2026, 23:39 UTC

Acquisitions, Mergers, Takeovers

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23 lut 2026, 23:31 UTC

Earnings

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23 lut 2026, 23:31 UTC

Earnings

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23 lut 2026, 23:28 UTC

Earnings

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23 lut 2026, 23:28 UTC

Earnings

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23 lut 2026, 23:28 UTC

Earnings

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23 lut 2026, 23:27 UTC

Earnings

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23 lut 2026, 23:24 UTC

Market Talk

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23 lut 2026, 22:38 UTC

Acquisitions, Mergers, Takeovers

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23 lut 2026, 22:31 UTC

Earnings

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 lut 2026, 22:24 UTC

Earnings

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23 lut 2026, 22:22 UTC

Earnings

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23 lut 2026, 22:22 UTC

Earnings

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23 lut 2026, 22:22 UTC

Earnings

Viva Energy FY Underlying Ebitda A$700.9 Million

23 lut 2026, 22:22 UTC

Earnings

Viva Energy Final Dividend 3.94 Australian Cents/Security

23 lut 2026, 22:21 UTC

Earnings

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23 lut 2026, 22:21 UTC

Earnings

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23 lut 2026, 22:20 UTC

Earnings

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Peer Comparison

Price change

Smith & Nephew PLC Forecast

Price Target

By TipRanks

11.53% upside

12 Months Forecast

Average 1,490.57 GBX  11.53%

High 1,650 GBX

Low 1,290 GBX

Based on 7 Wall Street analysts offering 12 month price targets forSmith & Nephew PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

7 ratings

5

Buy

2

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat